Kyprolis

Carfilzomib

In combination w/ dexamethasone or lenalidomide + dexamethasone for patients w/ relapsed or refractory multiple myeloma who have received 1-3 lines of therapy.

In combination w/ dexamethasone Administer as 30-min IV infusion once or 2 consecutive days wkly for 3 wk followed by 12-day rest period. Each 28-day period is considered 1 treatment cycle. Once wkly: Initially 20 mg/m² on day 1 of cycle 1. If tolerated, escalate dose to 70 mg/m² on days 8 & 15. Cycle 2 onwards: 70 mg/m² on days 1, 8 & 15. Take dexamethasone 40 mg PO/IV 30 min-4 hr before treatment on days 1, 8 & 15 of all cycles & on day 22 of cycles 1-9. Twice wkly: Initially 20 mg/m² on days 1 & 2 of cycle 1. If tolerated, escalate dose to 56 mg/m² on days 8, 9, 15 & 16 of cycle 1. Take dexamethasone 20 mg PO/IV 30 min-4 hr before treatment on days 1, 2, 8, 9, 15, 16, 22 & 23 of each 28-day cycle. In combination w/ lenalidomide & dexamethasone Administer as 10-min IV infusion on days 1, 2, 8, 9, 15 & 16 of each 28-day cycle in combination w/ lenalidomide & dexamethasone until cycle 12. Recommended starting dose: 20 mg/m² on days 1 & 2 of cycle 1. If tolerated, escalate dose to 27 mg/m² on day 8 of cycle 1. From cycle 13, administer on days 1, 2, 15 & 16 until cycle 18. Discontinue after cycle 18. Take lenalidomide 25 mg PO on days 1-21 & dexamethasone 40 mg PO/IV on days 1, 8, 15 & 22 of 28-day cycles.

Hypersensitivity. Lactation.

New onset or worsening of pre-existing cardiac failure (eg, CHF, pulmonary edema, decreased ejection fraction), cardiomyopathy, myocardial ischemia & infarction; NYHA class III & IV heart failure; tumor lysis syndrome; acute resp distress syndrome, resp failure & diffuse infiltrative pulmonary disease eg, pneumonitis, ILD; pulmonary arterial HTN; dyspnea; HTN; venous thromboembolic events; infusion-related reactions; haemorrhage; thrombocytopenia; thrombotic microangiopathy eg, TTP/hemolytic uremic syndrome; posterior reversible encephalopathy syndrome; progressive multifocal leukoencephalopathy. Asian patients. Concomitant use w/ OCs or hormonal contraception; melphalan & prednisone; immunosuppressives. May affect ability to drive or operate machinery. Acute renal failure. Hepatic toxicity & failure. Women of childbearing potential should use effective contraception. Not to be used during pregnancy & lactation. Ped patients. Elderly.

Anemia, neutropenia, thrombocytopenia; diarrhea, constipation, nausea, vomiting; fatigue, pyrexia, peripheral edema, asthenia; URTI, bronchitis, viral URTI, pneumonia; hypokalemia, hypocalcemia, hyperglycemia; muscle spasms, back pain; headache, peripheral neuropathies; insomnia; cough, dyspnea; rash; embolic & thrombotic events, HTN. Hemolytic uremic syndrome, HBV reactivation, GI perforation, pericarditis, cytomegalovirus infection including chorioretinitis, pneumonitis, enterocolitis, viremia, intestinal obstruction, acute pancreatitis.

Targeted Cancer Therapy

L01XG02 - carfilzomib ; Belongs to the class of proteasome inhibitors. Used in the treatment of cancer.

B